These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 21552302

  • 21. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
    Brammer JE, Stentz A, Gajewski J, Curtin P, Hayes-Lattin B, Kovacsovics T, Leis JF, Meyers G, Nemecek E, Subbiah N, Frires R, Palmbach G, Avraham GP, Slater S, Maziarz RT.
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
    [Abstract] [Full Text] [Related]

  • 22. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
    Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, Bashey A.
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
    [Abstract] [Full Text] [Related]

  • 23. High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.
    Al-Kadhimi Z, Gul Z, Chen W, Smith D, Abidi M, Deol A, Ayash L, Lum L, Waller EK, Ratanatharathorn V, Uberti J.
    Biol Blood Marrow Transplant; 2014 Jul; 20(7):979-85. PubMed ID: 24709007
    [Abstract] [Full Text] [Related]

  • 24. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
    Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Barón A, McSweeney PA.
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):217-25. PubMed ID: 16443519
    [Abstract] [Full Text] [Related]

  • 25. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, Ringden O, Urbano-Ispizua A, Saad A, Savani BN, Cooper B, Marks DI, Socie G, Schouten HC, Schoemans H, Abdel-Azim H, Yared J, Cahn JY, Wagner J, Antin JH, Verdonck LF, Lehmann L, Aljurf MD, MacMillan ML, Litzow MR, Solh MM, Qayed M, Hematti P, Kamble RT, Vij R, Hayashi RJ, Gale RP, Martino R, Seo S, Hashmi SK, Nishihori T, Teshima T, Gergis U, Inamoto Y, Spellman SR, Arora M, Hamilton BK.
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [Abstract] [Full Text] [Related]

  • 26. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 27. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
    Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M.
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
    [Abstract] [Full Text] [Related]

  • 28. Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.
    Kornblit B, Storer BE, Andersen NS, Maris MB, Chauncey TR, Petersdorf EW, Woolfrey AE, Flowers MED, Storb R, Maloney DG, Sandmaier BM.
    Blood; 2020 Sep 24; 136(13):1499-1506. PubMed ID: 32603426
    [Abstract] [Full Text] [Related]

  • 29. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS.
    Biol Blood Marrow Transplant; 2010 Mar 24; 16(3):333-43. PubMed ID: 19835971
    [Abstract] [Full Text] [Related]

  • 30. Mycophenolate mofetil-based salvage as acute GVHD prophylaxis after early discontinuation of tacrolimus and/or sirolimus.
    Ali H, Palmer J, Eroglu Z, Stiller T, Thomas SH, Khaled S, Shayani S, Parker P, Forman SJ, Nakamura R.
    Bone Marrow Transplant; 2015 Feb 24; 50(2):307-9. PubMed ID: 25365064
    [No Abstract] [Full Text] [Related]

  • 31. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
    Zohren F, Schroeder T, Czibere A, Fenk R, Bruns I, Kondakci M, Saure C, Haas R, Kobbe G.
    Bone Marrow Transplant; 2011 May 24; 46(5):747-55. PubMed ID: 20661230
    [Abstract] [Full Text] [Related]

  • 32. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.
    Kasper C, Sayer HG, Mügge LO, Schilling K, Scholl S, Issa MC, Höffken K.
    Bone Marrow Transplant; 2004 Jan 24; 33(1):65-9. PubMed ID: 14704658
    [Abstract] [Full Text] [Related]

  • 33. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation.
    Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E.
    Blood Adv; 2021 Mar 09; 5(5):1154-1163. PubMed ID: 33635333
    [Abstract] [Full Text] [Related]

  • 34. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florêncio R, Calixto R.
    Clin Transplant; 2009 Mar 09; 23(1):33-8. PubMed ID: 18727660
    [Abstract] [Full Text] [Related]

  • 35. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
    Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF.
    Blood; 2003 Feb 15; 101(4):1620-9. PubMed ID: 12393457
    [Abstract] [Full Text] [Related]

  • 36. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.
    Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO.
    Cancer; 2016 Nov 15; 122(21):3316-3326. PubMed ID: 27404668
    [Abstract] [Full Text] [Related]

  • 37. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
    Chen H, Liu KY, Liu DH, Xu LP, Han W, Chen YH, Huang XJ.
    Zhonghua Yi Xue Za Zhi; 2008 Aug 05; 88(30):2127-30. PubMed ID: 19080474
    [Abstract] [Full Text] [Related]

  • 38. A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
    Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM.
    Haematologica; 2014 Oct 05; 99(10):1624-31. PubMed ID: 25085357
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation.
    Offer K, Kolb M, Jin Z, Bhatia M, Kung AL, George D, Garvin JH, Robinson C, Sosna J, Karamehmet E, Satwani P.
    Biol Blood Marrow Transplant; 2015 Mar 05; 21(3):496-502. PubMed ID: 25536217
    [Abstract] [Full Text] [Related]

  • 40. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.
    Bejanyan N, Rogosheske J, DeFor T, Lazaryan A, Esbaum K, Holtan S, Arora M, MacMillan ML, Weisdorf D, Jacobson P, Wagner J, Brunstein CG.
    Biol Blood Marrow Transplant; 2015 May 05; 21(5):926-33. PubMed ID: 25655791
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.